"FDA"^^ . . "93957-54-1"^^ . . . "A synthetic lipid-lowering agent with antilipidemic and potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated antigen-presenting cells such as human vascular endothelial cells. Due to its anti-inflammatory effects mediated by alterations of lipid metabolism, fluvastatin may possess chemopreventive and therapeutic antineoplastic properties.NCI" . "CHEBI:38561"^^ . . "C24H26FNO4"^^ . "Fluvastatin"^^ . . "Fluvastatin"^^ . "C0082608"^^ . "CHEBI:5136"^^ . "C61768"^^ . "FLUVASTATINPTFDA4L066368AS" . "FluvastatinPTNCI" . "Fluvastatin"^^ . . "Pharmacologic Substance"^^ . "4L066368AS"^^ .